Evidence map›Paper›PMID 29713786›Full record

ArticlePsychopharmacology2018

Interest of new alkylsulfonylhydrazide-type compound in the treatment of alcohol use disorders.

Jérôme Jeanblanc, Erika Bourguet, Diana Sketriené, Céline Gonzalez, Gautier Moroy, Rémi Legastelois, Mathieu Létévé, Aurélie Trussardi-Régnier, Mickaël Naassila

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jérôme JeanblancGroupe de Recherche sur l'Alcool et les Pharmacodépendances (GRAP), INSERM U1247, Université de Picardie Jules Verne, C.U.R.S. (Centre Universitaire de Recherche en Santé), Chemin du Thil, 80000, Amiens, France.
Erika BourguetStructure Fédérative de Recherche-Champagne Ardenne Picardie Santé (SFR-CAP Santé), Amiens, France. erika.bourguet@univ-reims.fr.
Diana SketrienéGroupe de Recherche sur l'Alcool et les Pharmacodépendances (GRAP), INSERM U1247, Université de Picardie Jules Verne, C.U.R.S. (Centre Universitaire de Recherche en Santé), Chemin du Thil, 80000, Amiens, France.
Céline GonzalezGroupe de Recherche sur l'Alcool et les Pharmacodépendances (GRAP), INSERM U1247, Université de Picardie Jules Verne, C.U.R.S. (Centre Universitaire de Recherche en Santé), Chemin du Thil, 80000, Amiens, France.
Gautier MoroyMolécules Thérapeutiques In Silico (MTi), INSERM UMR-S 973, Université Paris Diderot, Sorbonne Paris Cité, 35 rue Hélène Brion, 75013, Paris, France.
Rémi LegasteloisGroupe de Recherche sur l'Alcool et les Pharmacodépendances (GRAP), INSERM U1247, Université de Picardie Jules Verne, C.U.R.S. (Centre Universitaire de Recherche en Santé), Chemin du Thil, 80000, Amiens, France.
Mathieu LétévéStructure Fédérative de Recherche-Champagne Ardenne Picardie Santé (SFR-CAP Santé), Amiens, France.
Aurélie Trussardi-RégnierStructure Fédérative de Recherche-Champagne Ardenne Picardie Santé (SFR-CAP Santé), Amiens, France.
Mickaël NaassilaGroupe de Recherche sur l'Alcool et les Pharmacodépendances (GRAP), INSERM U1247, Université de Picardie Jules Verne, C.U.R.S. (Centre Universitaire de Recherche en Santé), Chemin du Thil, 80000, Amiens, France. mickael.naassila@u-picardie.fr.ORCID http://orcid.org/0000-0002-9788-0918
Inserm · FRCentre National de la Recherche Scientifique · FRConseil Régional de Champagne-Ardenne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleRecent preclinical research suggested that histone deacetylase inhibitors (HDACIs) and specifically class I HDAC selective inhibitors might be useful to treat alcohol use disorders (AUDs).

objectiveThe objective of this study was to find a new inhibitor of the HDAC-1 isoenzyme and to test its efficacy in an animal model of AUDs.

methodsIn the present study, we prepared new derivatives bearing sulfonylhydrazide-type zinc-binding group (ZBG) and evaluated these compounds in vitro on HDAC-1 isoenzyme. The most promising compound was tested on ethanol operant self-administration and relapse in rats.

resultsWe showed that the alkylsulfonylhydrazide-type compound (ASH) reduced by more than 55% the total amount of ethanol consumed after one intracerebroventricular microinjection, while no effect was observed on motivation of the animals to consume ethanol. In addition, one ASH injection in the central amygdala reduced relapse.

conclusionsOur study demonstrated that a new compound designed to target HDAC-1 is effective in reducing ethanol intake and relapse in rats and further confirm the interest of pursuing research to study the exact mechanism by which such inhibitor may be useful to treat AUDs.

Indexed as

AlcoholismAnimalsEthanolHistone Deacetylase 1Histone Deacetylase InhibitorsMaleMolecular Docking SimulationMotivationRatsRats, Long-EvansSelf AdministrationSulfatasesTreatment OutcomealkylsulfataseEthanolHdac1 protein, ratHistone Deacetylase 1Histone Deacetylase InhibitorsSulfatasesAlkylsulfonylhydrazideEthanol self-administrationHistone deacetylaseInhibitionRatsZinc-binding group

Identifiers

PMID29713786
OpenAlexW2802717813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.